Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China
Contact: Study coordinator (Ning Jiang) · njiang117@njmu.edu.cn · +86 13605184783

Study leads

Xiangzhi Zhu
Study Director
Jiangsu Cancer Institute & Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Toripalimab · Surufatinib · Neoadjuvant Immunochemotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China